Evidence map›Paper›PMID 26302492›Full record

ArticlePloS one2015

Identification of the Acetylation and Ubiquitin-Modified Proteome during the Progression of Skeletal Muscle Atrophy.

Daniel J Ryder, Sarah M Judge, Adam W Beharry, Charles L Farnsworth, Jeffrey C Silva, Andrew R Judge

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Epigenetics of Skeletal Muscle Atrophy.International journal of molecular sciences · 2024
    Review
  8. Epigenetic control of skeletal muscle atrophy.Cellular & molecular biology letters · 2024
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Daniel J RyderDepartment of Physical Therapy, University of Florida, Gainesville, FL, United States of America.
Sarah M JudgeDepartment of Physical Therapy, University of Florida, Gainesville, FL, United States of America.
Adam W BeharryDepartment of Physical Therapy, University of Florida, Gainesville, FL, United States of America.
Charles L FarnsworthCell Signaling Technology, Danvers, MA, United States of America.
Jeffrey C SilvaCell Signaling Technology, Danvers, MA, United States of America.
Andrew R JudgeDepartment of Physical Therapy, University of Florida, Gainesville, FL, United States of America.
University of Florida · USCell Signaling Technology (United States) · US

Funding

Training In Rehabilitation and Neuromuscular PlasticityT32HD043730 · NICHD · UNIVERSITY OF FLORIDA · PI DAVID D FULLER · 2003 to 2026
$5.3M
FOXO signaling and skeletal muscle atrophyR01AR060209 · NIAMS · UNIVERSITY OF FLORIDA · PI JUDGE, ANDREW ROBERT · 2011 to 2021
$4.2M
NIAMS NIH HHS R01 AR060209NIAMS NIH HHS R01AR060209NICHD NIH HHS T32 HD043730NICHD NIH HHS T32-HD-043730
6 · The paper itself

Abstract

Skeletal muscle atrophy is a consequence of several physiological and pathophysiological conditions including muscle disuse, aging and diseases such as cancer and heart failure. In each of these conditions, the predominant mechanism contributing to the loss of skeletal muscle mass is increased protein turnover. Two important mechanisms which regulate protein stability and degradation are lysine acetylation and ubiquitination, respectively. However our understanding of the skeletal muscle proteins regulated through acetylation and ubiquitination during muscle atrophy is limited. Therefore, the purpose of the current study was to conduct an unbiased assessment of the acetylation and ubiquitin-modified proteome in skeletal muscle during a physiological condition of muscle atrophy. To induce progressive, physiologically relevant, muscle atrophy, rats were cast immobilized for 0, 2, 4 or 6 days and muscles harvested. Acetylated and ubiquitinated peptides were identified via a peptide IP proteomic approach using an anti-acetyl lysine antibody or a ubiquitin remnant motif antibody followed by mass spectrometry. In control skeletal muscle we identified and mapped the acetylation of 1,326 lysine residues to 425 different proteins and the ubiquitination of 4,948 lysine residues to 1,131 different proteins. Of these proteins 43, 47 and 50 proteins were differentially acetylated and 183, 227 and 172 were differentially ubiquitinated following 2, 4 and 6 days of disuse, respectively. Bioinformatics analysis identified contractile proteins as being enriched among proteins decreased in acetylation and increased in ubiquitination, whereas histone proteins were enriched among proteins increased in acetylation and decreased in ubiquitination. These findings provide the first proteome-wide identification of skeletal muscle proteins exhibiting changes in lysine acetylation and ubiquitination during any atrophy condition, and provide a basis for future mechanistic studies into how the acetylation and ubiquitination status of these identified proteins regulates the muscle atrophy phenotype.

Indexed as

Disease ProgressionAcetylationAmino Acid SequenceAnimalsGene ExpressionHumansMuscle ProteinsMuscle, SkeletalProtein Processing, Post-TranslationalProteomeRatsSignal TransductionUbiquitinMuscle ProteinsProteomeUbiquitin

Identifiers

PMID26302492
PMCPMC4547751
OpenAlexW1926390858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.